ES2162933T3 - Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft). - Google Patents

Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).

Info

Publication number
ES2162933T3
ES2162933T3 ES95927503T ES95927503T ES2162933T3 ES 2162933 T3 ES2162933 T3 ES 2162933T3 ES 95927503 T ES95927503 T ES 95927503T ES 95927503 T ES95927503 T ES 95927503T ES 2162933 T3 ES2162933 T3 ES 2162933T3
Authority
ES
Spain
Prior art keywords
sub
instituted
group
replaced
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95927503T
Other languages
English (en)
Inventor
Michael D Varney
William H Romines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2162933T3 publication Critical patent/ES2162933T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DE FORMULA (I), LOS CUALES ESTAN EN EQUILIBRIO CON SUS TAUTOMEROS 4-HIDROXI Y ESTAN EN FORMA DE MEZCLAS DIAESTEREOMERICAS, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES SON POTENTES INHIBIDORES DE GARFT. A ES S, CH{SUB,2} O SE; Z ES UN ALQUILO C{SUB,1}-C{SUB,3} SUSTITUIDO O INSUSTITUIDO, ALQUENILO C{SUB,2}-C{SUB,3}, ALQUINILO C{SUB,2}-C{SUB,3} O GRUPO AMINO, O S O O; X ES UN GRUPO ALQUILO C{SUB,1}-C{SUB,6} SUSTITUIDO O INSUSTITUIDO; UN GRUPO ALQUINILO C{SUB,2}-C{SUB,6} SUSTITUIDO O INSUSTITUIDO; UN GRUPO ALQUINILO C{SUB,2}-C{SUB,6} SUSTITUIDO O INSUSTITUIDO; -C(()O())E, EN DONDE E ES HIDROGENO, UN GRUPO ALQUILO C{SUB,1}-C{SUB,3} SUSTITUIDO O INSUSTITUIDO, UN GRUPO ALQUENILO C{SUB,2}-C{SUB,3} SUSTITUIDO O INSUSTITUIDO, UN GRUPO ALQUINILO C{SUB,2}-C{SUB,3} SUSTITUIDO O INSUSTITUIDO, UN GRUPO ALCOXI OC{SUB,1}-C{SUB,3} SUSTITUIDO O INSUSTITUIDO, O NR{SUB,10}R{SUB,11}, EN DONDE R{SUB,10} Y R{SUB,11} SE SELECCIONAN INDEPENDIENTEMENTE DE HIDROGENO, GRUPOS ALQUILO C{SUB,1}-C{SUB,3} SUSTITUIDOS E INSUSTITUIDOS, GRUPOS ALQUENILO C{SUB,2}-C{SUB,3} SUSTITUIDOS E INSUSTITUIDOS, GRUPOS ALQUINILO C{SUB,2}-C{SUB,3} SUSTITUIDOS E INSUSTITUIDOS; NR{SUB,10}R{SUB,11}, EN DONDE R{SUB,10} Y R{SUB,11} SE DEFINEN INDEPENDIENTEMENTE COMO SE ESTABLECE ANTES; HIDROXILO, NITRO; SR{SUB,12} EN DONDE R{SUB,12} ES HIDROGENO, UN GRUPO ALQUILO C{SUB,1}-C{SUB,6} SUSTITUIDO O INSUSTITUIDO, UN GRUPO ALQUENILO C{SUB,2}-C{SUB,6} SUSTITUIDO O INSUSTITUIDO O UN GRUPO ALQUINILO C{SUB,2}-C{SUB,6} SUSTITUIDO O INSUSTITUIDO; CIANO; O UN GRUPO ALCOXI C{SUB,1}-C{SUB,3} SUSTITUIDO O INSUSTITUIDO; Y R{SUB,1} Y R{SUB,2} SON INDEPENDIENTEMENTE HIDROGENO O UNA ESTRUCTURA QUE FORMA CON EL CO{SUB,2} INCORPORADO UN GRUPO DE ESTER RAPIDAMENTE HIDROLIZABLE. ESTOS COMPUESTOS Y SUS SALES SON UTILES COMO AGENTES ANTIPROLIFERATIVOS. LA INVENCION TAMBIEN PERTENECE A COMPOSICIONES FARMACEUTICAS Y A METODOS QUE EMPLEAN DICHOS COMPUESTOS COMO AGENTES INHIBIDORES O ANTIPROLIFERATIVOS DE GARFT. LA INVENCION TAMBIEN SE REFIERE A COMPUESTOS UTILES COMO INTERMEDIARIOS PARA LA PREPARACION DE DICHOS COMPUESTOS, Y A SUS SINTESIS.
ES95927503T 1994-07-28 1995-07-28 Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft). Expired - Lifetime ES2162933T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/281,639 US5608082A (en) 1994-07-28 1994-07-28 Compounds useful as antiproliferative agents and GARFT inhibitors

Publications (1)

Publication Number Publication Date
ES2162933T3 true ES2162933T3 (es) 2002-01-16

Family

ID=23078167

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95927503T Expired - Lifetime ES2162933T3 (es) 1994-07-28 1995-07-28 Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).

Country Status (20)

Country Link
US (2) US5608082A (es)
EP (1) EP0773943B1 (es)
JP (1) JPH10503762A (es)
KR (1) KR100380610B1 (es)
CN (2) CN1091770C (es)
AT (1) ATE206122T1 (es)
AU (1) AU697138B2 (es)
CA (1) CA2195420A1 (es)
DE (1) DE69522945T2 (es)
DK (1) DK0773943T3 (es)
ES (1) ES2162933T3 (es)
FI (1) FI112079B (es)
MX (1) MX9700675A (es)
NO (1) NO308248B1 (es)
NZ (1) NZ290703A (es)
PT (1) PT773943E (es)
RU (1) RU2152945C2 (es)
SI (1) SI0773943T1 (es)
TW (1) TW432062B (es)
WO (1) WO1996003406A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831100A (en) * 1995-06-07 1998-11-03 Agouron Pharmaceuticals, Inc. Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates
WO2001016121A1 (en) * 1999-08-31 2001-03-08 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
AU2002306413A1 (en) * 2001-02-16 2002-10-15 Eli Lilly And Company Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
MXPA04002537A (es) 2001-10-12 2004-05-31 Warner Lambert Co Alquinos como inhibidores de metaloproteinasa de matriz.
WO2003033478A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2003249505A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
WO2004113337A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent synthesis of a garft inhibitor containing a methyl substitute thiophene core and a tetrahydropyrido`2,3-d! pyrimidine ring system and intermediates therefor
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
MY164457A (en) 2005-09-07 2017-12-15 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
RS20080525A (en) 2006-05-09 2009-09-08 Pfizer Products Inc., Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US8252804B2 (en) * 2008-10-01 2012-08-28 Duquesne University Of The Holy Spirit Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
ES2594409T3 (es) 2011-02-23 2016-12-20 Lupin Limited Derivados de heteroarilo como moduladores del nAChR á7
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
US20140309275A1 (en) * 2011-09-29 2014-10-16 Emory University Sphingosine Analogs, Compositions, and Methods Related Thereto
IN2014MN01756A (es) 2012-03-06 2015-07-03 Lupin Ltd
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN115634228B (zh) * 2021-07-20 2024-03-19 首都医科大学 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4927828A (en) * 1985-03-08 1990-05-22 The Trustees Of Princeton University Diastereoisomeric tetrahydropyrido-(2,3,d) pyrimidine derivatives
US4684653A (en) * 1985-03-08 1987-08-04 The Trustees Of Princeton University Pyrido(2,3-d)pyrimidine derivatives
US5026851A (en) * 1985-03-08 1991-06-25 The Trustees Of Princeton University Pyrido[2,3-]pyrimidine derivatives
US4831037A (en) * 1987-04-20 1989-05-16 The Trustees Of Princeton University 4 (3H)-oxo-5,6,7,8-tetrahydropyrido-(2,3-d)pyrimidine derivatives
US4988813A (en) * 1986-10-20 1991-01-29 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US4895946A (en) * 1987-10-26 1990-01-23 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US4889859A (en) * 1988-02-05 1989-12-26 The Trustees Of Princeton University Pyrido[2,3-d]pyrimidine derivatives
US4882333A (en) * 1988-05-25 1989-11-21 The Trustess Of Princeton University N-(5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives
US4882334A (en) * 1988-05-25 1989-11-21 The Trustees Of Princeton University N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4871746A (en) * 1988-05-31 1989-10-03 The Trustees Of Princeton University N-[N-(tetrahydropyrido[2,3-D]pyrimidinylmethyl)-aminomethylbenzoyl]glutamic acid derivatives as neoplastic growth inhibitors
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
IL99500A0 (en) * 1990-09-17 1992-08-18 Agouron Pharma Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
US5217974A (en) * 1991-03-29 1993-06-08 Eli Lilly And Company Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
US5969136A (en) * 1992-10-15 1999-10-19 Eli Lilly And Company Cyclization for preparing antifolate compounds
CA2151588C (en) * 1992-12-16 2002-03-19 Michael D. Varney Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone

Also Published As

Publication number Publication date
EP0773943A1 (en) 1997-05-21
AU697138B2 (en) 1998-09-24
US5646141A (en) 1997-07-08
AU3151795A (en) 1996-02-22
TW432062B (en) 2001-05-01
US5608082A (en) 1997-03-04
NO970349D0 (no) 1997-01-27
DE69522945T2 (de) 2002-03-28
NO970349L (no) 1997-03-12
CA2195420A1 (en) 1996-02-08
DK0773943T3 (da) 2002-03-04
EP0773943B1 (en) 2001-09-26
DE69522945D1 (de) 2001-10-31
ATE206122T1 (de) 2001-10-15
NZ290703A (en) 1998-11-25
FI970317A (fi) 1997-03-05
CN1394857A (zh) 2003-02-05
FI970317A0 (fi) 1997-01-24
CN1154110A (zh) 1997-07-09
PT773943E (pt) 2002-01-30
NO308248B1 (no) 2000-08-21
SI0773943T1 (en) 2001-12-31
CN1091770C (zh) 2002-10-02
KR100380610B1 (ko) 2003-08-27
RU2152945C2 (ru) 2000-07-20
MX9700675A (es) 1997-04-30
WO1996003406A1 (en) 1996-02-08
FI112079B (fi) 2003-10-31
JPH10503762A (ja) 1998-04-07

Similar Documents

Publication Publication Date Title
ES2162933T3 (es) Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).
ES2143238T3 (es) Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
ES2188957T3 (es) N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
AR007456A1 (es) Compuestos derivados de indazol sustituido y composiciones farmaceuticas que lo contienen
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
AR015103A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones que los contienen e intermediarios
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
GT200100132A (es) Derivados de pirazol
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
UY25987A1 (es) Procedimiento para preparar complejo del inhibidor de ras-fa rnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2- hidroxipropil-beta-ciclodextrina y método
CO4810381A1 (es) Combinacion eficaz para el tratamiento de la impotencia
ES2059804T3 (es) Procedimiento de preparacion de eteres de oxima de propenona.
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
PL374019A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
ES2159345T3 (es) Indazolcarboxamidas.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 773943

Country of ref document: ES